🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06241326
Recruiting Observational

Immunotherapy for Hepatocellular Carcinoma

NCT06241326 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Started
2024-03-01
Last updated
2024-04-10

Condition(s) studied

Hepatocellular CarcinomaImmunotherapy

Investigational drug(s) / intervention(s)

Immunotherapy-based Combination Therapies

Immunotherapy-based Combination Therapies: immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions

Study summary

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Aged after 18 years (18 is included). 2. Hepatocellular carcinoma diagnosed by pathology or imaging. 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens. 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations. 5. Patients voluntarily enroll in this study. Exclusion Criteria: 1. Pregnant or lactating women. 2. Other conditions regimented at investigators' discretion.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jiangsu Province Hospital Nanjing Jiangsu Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06241326 on ClinicalTrials.gov ↗ ← All trials in China